Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and PertuzumabEvelyn Yao, Klaus P. Hoeflich, Wei Zhou et al.|Clinical Cancer Research|2009Cited by 124
PPM1H Is a p27 Phosphatase Implicated in Trastuzumab ResistanceSi Tuen Lee-Hoeflich, Howard M. Stern, Thinh Q. Pham et al.|Cancer Discovery|2011Cited by 59
BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 StudyDavid Lavie, Rosa Ayala, Chun Yew Fong et al.|Blood|2023Cited by 7
MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II StudyRosa Ayala, David Lavie, Nieves López‐Muñoz et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 2